FR3026744B1 - Methode de generation de progeniteurs de cellules t - Google Patents

Methode de generation de progeniteurs de cellules t Download PDF

Info

Publication number
FR3026744B1
FR3026744B1 FR1459539A FR1459539A FR3026744B1 FR 3026744 B1 FR3026744 B1 FR 3026744B1 FR 1459539 A FR1459539 A FR 1459539A FR 1459539 A FR1459539 A FR 1459539A FR 3026744 B1 FR3026744 B1 FR 3026744B1
Authority
FR
France
Prior art keywords
cell progenitors
paris
ligand
generation
institute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1459539A
Other languages
English (en)
French (fr)
Other versions
FR3026744A1 (fr
Inventor
Emmanuelle Six
Marina Cavazzana
Isabelle Andre
Chantal Lagresle-Peyrou
Salima Hacein-Bey-Abina
Christian Reimann
Chappedelaine Corinne De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Imagine Institut Des Maladies Gene Fr
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Original Assignee
Fondation Imagine Inst Des Maladies Genetiques
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1459539A priority Critical patent/FR3026744B1/fr
Application filed by Fondation Imagine Inst Des Maladies Genetiques, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Descartes filed Critical Fondation Imagine Inst Des Maladies Genetiques
Priority to EP22152734.4A priority patent/EP4036224A1/fr
Priority to US15/516,731 priority patent/US12071635B2/en
Priority to DK15771979.0T priority patent/DK3204492T3/da
Priority to JP2017537016A priority patent/JP6898240B2/ja
Priority to PCT/EP2015/072889 priority patent/WO2016055396A1/fr
Priority to HUE15771979A priority patent/HUE059468T2/hu
Priority to EP15771979.0A priority patent/EP3204492B1/fr
Priority to CA2963756A priority patent/CA2963756C/fr
Priority to ES15771979T priority patent/ES2914082T3/es
Priority to PL15771979.0T priority patent/PL3204492T3/pl
Priority to PT157719790T priority patent/PT3204492T/pt
Publication of FR3026744A1 publication Critical patent/FR3026744A1/fr
Priority to JP2020209370A priority patent/JP2021072779A/ja
Application granted granted Critical
Publication of FR3026744B1 publication Critical patent/FR3026744B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
FR1459539A 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t Active FR3026744B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t
PL15771979.0T PL3204492T3 (pl) 2014-10-06 2015-10-05 Sposób generowania komórek progenitorowych limfocytów t
DK15771979.0T DK3204492T3 (da) 2014-10-06 2015-10-05 Fremgangsmåde til generering af t-celleforløbere
JP2017537016A JP6898240B2 (ja) 2014-10-06 2015-10-05 Ｔ細胞前駆細胞を生成するための方法
PCT/EP2015/072889 WO2016055396A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t
HUE15771979A HUE059468T2 (hu) 2014-10-06 2015-10-05 Módszer T-sejt progenitorok generálására
EP22152734.4A EP4036224A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t
CA2963756A CA2963756C (fr) 2014-10-06 2015-10-05 Methode de generation de progeniteurs de cellules t
ES15771979T ES2914082T3 (es) 2014-10-06 2015-10-05 Procedimiento de generación de progenitores de células T
US15/516,731 US12071635B2 (en) 2014-10-06 2015-10-05 Method for generating T-cell progenitors
PT157719790T PT3204492T (pt) 2014-10-06 2015-10-05 Método de geração de progenitores de células t
EP15771979.0A EP3204492B1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t
JP2020209370A JP2021072779A (ja) 2014-10-06 2020-12-17 Ｔ細胞前駆細胞を生成するための方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t

Publications (2)

Publication Number Publication Date
FR3026744A1 FR3026744A1 (fr) 2016-04-08
FR3026744B1 true FR3026744B1 (fr) 2024-04-19

Family

ID=52102849

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1459539A Active FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t

Country Status (11)

Country Link
US (1) US12071635B2 (enExample)
EP (2) EP3204492B1 (enExample)
JP (2) JP6898240B2 (enExample)
CA (1) CA2963756C (enExample)
DK (1) DK3204492T3 (enExample)
ES (1) ES2914082T3 (enExample)
FR (1) FR3026744B1 (enExample)
HU (1) HUE059468T2 (enExample)
PL (1) PL3204492T3 (enExample)
PT (1) PT3204492T (enExample)
WO (1) WO2016055396A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
CA3096812A1 (en) * 2018-04-10 2019-10-17 Stichting Sanquin Bloedvoorziening Chimeric notch receptors
CN116615461A (zh) 2020-11-30 2023-08-18 醣基生医股份有限公司 用于富集细胞的抗体
US20260152721A1 (en) 2021-11-04 2026-06-04 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
KR20250152088A (ko) 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
WO2025012449A1 (en) * 2023-07-12 2025-01-16 Smart Immune Biobank of cellular banks having specific homozygous hla haplotypes and uses thereof for treating patients
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
WO2025255678A1 (en) * 2024-06-14 2025-12-18 Stemcell Technologies Canada Inc. Compositions and methods for generating lymphoid lineage cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
EP1666589B1 (en) * 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA2737193A1 (en) 2008-09-12 2010-03-18 Universidade Federal De Sao Paulo - Unifesp Ischemic tissue cell therapy
US8772028B2 (en) 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
US8871510B2 (en) * 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
EP3590520B1 (en) 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Compositions for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) * 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
WO2016039933A1 (en) * 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders

Also Published As

Publication number Publication date
EP3204492A1 (fr) 2017-08-16
PL3204492T3 (pl) 2022-07-25
JP2017531448A (ja) 2017-10-26
CA2963756A1 (fr) 2016-04-14
ES2914082T3 (es) 2022-06-07
EP3204492B1 (fr) 2022-03-09
ES2914082T8 (es) 2022-06-16
WO2016055396A1 (fr) 2016-04-14
US12071635B2 (en) 2024-08-27
EP4036224A1 (fr) 2022-08-03
HUE059468T2 (hu) 2022-12-28
US20180208895A1 (en) 2018-07-26
JP6898240B2 (ja) 2021-07-07
PT3204492T (pt) 2022-05-30
CA2963756C (fr) 2024-01-02
JP2021072779A (ja) 2021-05-13
DK3204492T3 (da) 2022-06-07
FR3026744A1 (fr) 2016-04-08

Similar Documents

Publication Publication Date Title
JOP20220225B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
Gümbel et al. Cold atmospheric plasma in the treatment of osteosarcoma
Wolff et al. Combination treatment with cold physical plasma and pulsed electric fields augments ROS production and cytotoxicity in lymphoma
Zhang et al. Cyclic mechanical stretching promotes migration but inhibits invasion of rat bone marrow stromal cells
CY1126148T1 (el) Καινοτομος χιμαιρικη πρωτεϊνη ειδικη για τις cd137 και pd-l1
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
DOP2015000162A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
EA201792041A1 (ru) Модифицированные гамма-дельта-t-клетки и их применение
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
MX388202B (es) Métodos para generar productos de esmalte in vitro.
MX2022000111A (es) Moleculas de union a claudina-6 y usos de las mismas.
JOP20190155A1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
MX2024005705A (es) Composiciones de liquidos ionicos.
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
EP4236937C0 (en) PYRIMIDINE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED THERE WITH THE SEROTONIN 5-HT2A RECEPTOR
CY1115223T1 (el) Αντι-μελαγχολικο φαρμακο που παρασκευαζεται με υλικα camp απο τζιτζιφα
EP4382123A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SMALL CELL LUNG CANCER
Mohamed et al. Immunomodulatory effects of non-thermal plasma in a model for latent HIV-1 infection: implications for an HIV-1-specific immunotherapy
PL379549A1 (pl) Autologiczne, indukujące tolerancję na antygeny własne komórki pochodzenia monocytarnego oraz ich zastosowanie w preparatach farmaceutycznych
EP4236942A4 (en) ISOXAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED THERETO
Keßler et al. Scalable and Continuous Generation of Plasma-Treated Solutions Designed for Healthcare Applications

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20160408

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

CD Change of name or company name

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20221006

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20221006

Owner name: FONDATION IMAGINE - INSTITUT DES MALADIES GENE, FR

Effective date: 20221006

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Effective date: 20221006

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12